A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma

Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis.

(2017) J. D. Hainsworth et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

A Multicenter Phase II Study of Single-Agent Enzastaurin in Previously Treated Waldenstrom Macroglobulinemia

(2012) I. M. Ghobrial et al.   CLINICAL CANCER RESEARCH

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma

(2011) Irene M. Ghobrial et al.   AMERICAN JOURNAL OF HEMATOLOGY

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

(2011) M. Q. Lacy et al.   BLOOD

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer

(2009) A.-R. Hanauske et al.   ANNALS OF ONCOLOGY

Targeting Angiogenesis via a c-Myc/Hypoxia-Inducible Factor-1 -Dependent Pathway in Multiple Myeloma

(2009) J. Zhang et al.   CANCER RESEARCH

Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation

(2008) Matthew J. Streetly et al.   BRITISH JOURNAL OF HAEMATOLOGY

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma

(2007) F. Morschhauser et al.   ANNALS OF ONCOLOGY